International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPIAmy S. Ruppert, Norbert Schmitz|Blood|2020Cited by 372
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Nirav N. Shah et al.|New England Journal of Medicine|2023Cited by 213
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinibAdam S. Kittai, Jennifer A. Woyach, Cecelia Miller et al.|Blood|2021Cited by 61
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Nirav N. Shah et al.|The Lancet Haematology|2024Cited by 37
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N. Shah, Jennifer R. Brown, Michael Wang et al.|Haematologica|2024Cited by 12